Inhaled antibiotics aim to beat pneumonia in ECMO patients

NCT ID NCT06602557

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study investigates whether inhaling the antibiotic amikacin can better treat pneumonia caused by gram-negative bacteria in patients on veno-arterial ECMO (a heart-lung bypass machine). Standard antibiotics often fail in these patients, possibly because the bypass reduces blood flow to the lungs, limiting drug delivery. The trial compares inhaled amikacin plus standard care versus standard care alone, measuring bacterial clearance after five days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Amikacin (inhaled)
What this could lead to
If it works, this could offer a new way to treat pneumonia in critically ill patients on ECMO, potentially reducing treatment failure.
What could go wrong
This is a small early-phase trial, so results may not apply broadly. Inhaled antibiotics can cause airway irritation or bronchospasm, and the drug may not reach infected areas effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTRACORPOREAL MEMBRANE OXYGENATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.